Stopping the wave of neurodegeneration at its source
Harnessing biophysics to target fleeting intermediates in disease pathways
Targeting Fleeting Intermediates
We are taking an entirely new approach to treating neurodegeneration, targeting the fleeting protein intermediates that are central to many neurodegenerative disease pathways but have been beyond the reach of conventional drug discovery approaches until now.
Discovery Platform
We have built a broad drug discovery platform to target the transient, unstable protein intermediates in amyloid disease pathways—toxic oligomers—with small-molecule drugs that interrupt the molecular mechanisms driving their formation.
Pipeline
We are focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.
